Howarth Sophie, Ho Tak-Wai, Wimbury James, Casey Ruth
University of Cambridge, Cambridge, UK.
Department of Diabetes and Endocrinology, Cambridge Cancer Centre and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Clin Endocrinol (Oxf). 2025 Mar;102(3):344-354. doi: 10.1111/cen.15188. Epub 2024 Dec 30.
The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre- and peri-operatively for patients undergoing surgical resection and as part of the long-term management for patients with inoperable or metastatic disease. Hypoglycaemia symptoms are frequently pervasive and disabling, with many patients showing impaired hypoglycaemia awareness that can lead to life-threatening severe hypoglycaemia. Herein, we review the literature and describe our tertiary centre experience in the mutli-disciplinary management of hypoglycaemia for patients with proven insulinomas. We propose a stepwise algorithm for the management of hypoglycaemia, stratified by localised versus metastatic disease. We discuss our strategy for the nutritional management of hypoglycaemia, reviewing the evidence for the use of cornstarch products and artificial nutrition. We discuss pharmacological management including diazoxide, somatostatin receptor antagonists (SSAs), everolimus and glucocorticoids, in addition to other therapeutic interventions such as peptide receptor radionuclide therapy (PRRT) and endoscopic ablation.
低血糖的管理在胰岛素瘤患者的护理中至关重要。对于接受手术切除的患者,术前和围手术期的血糖监测与调控需要密切关注,而对于无法手术或转移性疾病患者,这也是长期管理的一部分。低血糖症状常常普遍存在且使人衰弱,许多患者存在低血糖意识受损的情况,这可能导致危及生命的严重低血糖。在此,我们回顾相关文献,并描述我们三级中心在确诊胰岛素瘤患者低血糖多学科管理方面的经验。我们提出一种按局限性疾病与转移性疾病分层的低血糖管理逐步算法。我们讨论低血糖营养管理策略,回顾使用玉米淀粉产品和人工营养的证据。我们讨论药物管理,包括二氮嗪、生长抑素受体拮抗剂(SSAs)、依维莫司和糖皮质激素,此外还讨论其他治疗干预措施,如肽受体放射性核素治疗(PRRT)和内镜消融。